原位腺癌或微浸润腺癌切除术后肺癌患者的十年随访:楔形切除可治愈
本研究回顾性分析了2007年12月至2012年12月切除的肺腺癌患者,纳入病理为原位腺癌(53例)或微浸润腺癌(72例)者,中位随访111个月。结果显示两者10年无复发生存率均为100%,10年总生存率分别为98.1%和97.2%,肺叶切除与楔形切除的无复发生存无差异,术后第二原发肺癌风险分别为8.4%和4.3%(P=.298)。
要点
- 原位腺癌和微浸润腺癌切除后10年无复发生存率均为100%。
- 10年总生存率原位腺癌98.1%、微浸润腺癌97.2%。
- 肺叶切除与楔形切除的10年无复发生存无差异。
核心结论
- 病理为原位腺癌和微浸润腺癌的患者切除术后10年随访期间无复发,与手术方式无关;手术可治愈这些患者,对于位置合适的结节楔形切除是首选手术方式。
研究设计与样本
- 回顾性分析2007年12月至2012年12月间切除的肺腺癌患者,重新评估1696例组织学后纳入53例原位腺癌和72例微浸润腺癌,分析术后生存和第二原发肺癌风险。
主要发现
- 125例患者中86例(68.8%)为女性,114例(91.2%)不吸烟,78例(62.4%)接受楔形切除,中位随访111个月。
- 原位腺癌和微浸润腺癌的10年无复发生存率均为100%,10年总生存率分别为98.1%和97.2%。
- 肺叶切除与楔形切除患者的10年无复发生存率无差异。
- EGFR突变在65例接受突变分析的患者中检出率为63.1%(41/65)。
- 原位腺癌和微浸润腺癌术后10年第二原发肺癌风险分别为8.4%和4.3%(P=.298),与EGFR突变状态无关(P=.525)。
临床怎么用
- 作者认为手术可治愈原位腺癌和微浸润腺癌患者,对于位置合适的结节楔形切除是首选手术方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to reveal the long-term outcomes of patients with lung cancer with adenocarcinoma in situ or minimally invasive adenocarcinoma after resection, in the context of the different surgical resection types. METHODS: Patients with lung adenocarcinoma who underwent resection between December 2007 and December 2012 were reviewed. Patients with pathological adenocarcinoma in situ or minimally invasive adenocarcinoma were enrolled. Postoperative survival and risk of developing second primary lung cancer were analyzed. RESULTS: After reevaluating the histological findings of 1696 patients with lung adenocarcinoma, we enrolled 53 with adenocarcinoma in situ and 72 with minimally invasive adenocarcinoma for analyses. Of all 125 patients with adenocarcinoma in situ/minimally invasive adenocarcinoma, 86 (68.8%) were female, 114 (91.2%) were nonsmokers, and most of them (78, 62.4%) underwent wedge resection. The median follow-up period after surgery was 111 months. The 10-year recurrence-free survivals of adenocarcinoma in situ and minimally invasive adenocarcinoma were all 100%, and the 10-year overall survivals of adenocarcinoma in situ and minimally invasive adenocarcinoma were 98.1% and 97.2%, respectively. There was no difference in 10-year recurrence-free survival between patients who underwent lobectomy and wedge resection. EGFR mutations were detected in 63.1% (41/65) of patients who underwent mutational analysis. The risks of developing second primary lung cancer for adenocarcinoma in situ and minimally invasive adenocarcinoma 10 years after resection were 8.4% and 4.3% (P = .298), respectively, and were not correlated with EGFR mutation status (P = .525). CONCLUSIONS: Pathological adenocarcinoma in situ and minimally invasive adenocarcinoma have no recurrence during 10-year follow-up after resection, regardless of surgical procedure types. Surgery is curative for these patients, and wedge resection is the preferred surgical procedure for nodules in the proper location.
引用
- Li D, Deng C, Wang S, et al. Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative. J Thorac Cardiovasc Surg. 2022. PMID: 35965138. doi:10.1016/j.jtcvs.2022.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。